Skip to content

qMRI-LIFT

Quantitative MRI to non-invasively measure LIver FuncTion in patients with hepatic cancer - qMRI-LIFT

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON57890
Enrollment
30
Registered
2025-02-25
Start date
2025-10-30
Completion date
Unknown
Last updated
2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma, colorectal liver metastasis, liver function

Interventions

We use multiparametric MRI techniques, such as DCE-MRI, MR elastography and diffusion weighted techniques in this study. These techniques can measure multiple aspects of the liver such as perfusion, s

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a participant must meet all of the following criteria:18 years or olderSigned informed consent obtained prior to any study-specific procedurePatient diagnosed with one or more liver lesions who are scheduled for a HBS scan prior to a major hepatectomy. Origin of liver lesion can be: Primary hepatocellular carcinoma Hilar (Klatskin), intrahepatic or perihilar cholangiocarcinomaColorectal liver metastases

Exclusion criteria

Exclusion criteria: A potential participant who meets any of the following criteria will be excluded from participation in this study:Age <18 yearsNot able to sign informed consentGeneral contraindications for MRIChronic renal insufficiency or eGFR < 30 ml/min/1.73 m2Known or family history of congenital prolonged QT-syndromePrior history of arrhythmia after the use of cardiac repolarisation time prolonging drugsPrior history of allergic reaction to gadolinium-containing compoundsPrior history of asthma bronchiale

Design outcomes

Primary

MeasureTime frame
The main study parameter is the liver function measured with DCE MRI. This DCE MRI liver function will be compared to the liver function measured with HBS (the reference standard). 

Secondary

MeasureTime frame
The parameters calculated from all MP-qMRI scans will be correlated to the degree of steatosis, inflammation and fibrosis present in the resected non-tumorous liver. The following MP-qMRI parameters will be considered:Fat fraction measured with PDFFDiffusion and perfusion fraction measured with IVIM MRIStiffness and viscosity measured with MRET2* and T1 relaxivityThe MP-qMRI parameters mentioned in the previous point, will also be correlated to the liver function measured with HBS. The MP-qMRI parameters prior to the liver augmentation procedure will be compared to the parameters after the liver augmentation procedure. The change in liver function measured with MP-qMRI will be compared to the change in liver function measured with HBS. 

Countries

Netherlands

Contacts

Public ContactN.P.M. Wassenaar

Amsterdam UMC

secretariaat3t@amc.uva.nl020-5668368

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)